You are here

Duodenal ülser tedavisinde günde iki doz 300 mg ranitidin kullanımının etkinlik ve güvenilirliği

The efficacy and safety of 300mg bid ranitidine in treatment of duodenal

Journal Name:

Publication Year:

Keywords (Original Language):

Abstract (2. Language): 
Twenty patients with duodenal ulcer, measuring at least 5 mm or more in its larger diameter endoscopically were employed 300 mg bid ranitidine for 4 weeks. The patients were assessed endoscopically and symptomatically after 4 weeks. In 16 of 1~ (94.1 %) patients, pain was relieved in 1.6 days (mean) and ulcer was healed endoscopically in 4 weeks and no side effect was detected, li e concluded that 300 mg bid ranitidine is more effective and safe. [Journal of Turgut Özal Medical Center 1(2): 108-111.1994/
Abstract (Original Language): 
Endoskopik olarak büyük çapı en az 5 mm veya daha büyük duodenal ülseri bulunan 20 hastaya dört hafta süre ile sabah aksam 300 er mg ranitidin tedavisi verildi. Hastalar 4 hafta sonra endoskopik ve klinik olarak değerlendirildi. Kontrol edilebilen H hastanın 16'sında (% 94.1) ülser ağrısı ortalama 1.6 günde geçmiş, dört haftada ülser endoskopik olarak iyileşmişti. İlaç kullanımına ait yan etkiyle karşılaşılmadı. Günde iki doz 300 mg ranitidin verilmesinin daha etkili ve güvenilir olduğu sonucuna varıldı. /Turgut Özal Tıp Merkezi Dergisi 1(2): 108-111.19941
108-111

REFERENCES

References: 

1. Katz KD. Practical pharmacology and cost-
effective management of peptic ulcer disease. Am J Surg 1992; 349-59.
2. Soil AH. Pathogenesis of peptic ulcer and implications for therapy. N Engl J Med 1990; 322:909-16.
3. Welsh JD. Diet therapy of peptic ulcer disease. Gastroenterology 1977; 72: 740-5.
4. Ippoliti AF, Maxwell V, Isenberg JI. Effect of various forms of milk on gastric-acid secretion studies in patients with duodenal ulcer and normal subjects. Ann Intern Med 1976; 84: 286-9.
5. Henn RM, Isenbert JI, Maxwell V, Sturdevant RAL. Inhibition of gastric acid secretion by cimetidine in patients with duodenal ulcer. N Engl J Med 1975; 293: 371.
6. McGuigan JE. Consideration of the adverse effects of cimetidine. Gastroenterology 1981; 80: 181-92
7. Lewis JH. Hepatic effects of drugs used in the treatment of peptic ulcer disease. Gastroenterology 1987; 82: 987-1003.
8. Kimblatt BJ, Carra FB, Calleri F, et al. Dose and serum concentration relationship in cimetidine-associated mental confusion. Gastroenterology 1980; 78: 791-5.
9. Acet
A
, Ölmez E. Histamin H2 -reseptör blokörleri. Turgut Özal Tıp Merkezi Dergisi 1994; 1: 53-64.
10. Farley A, Levesque D, Pare P, et al. Comparative trial of ranitidine 300 mg at night with ranitidine 150 mg twice daily in the treatment of duodenal and gastric ulcer. Am J Gastroenterol 1980; 80. 665-8.
11. Zeldis JB, Friedman LS, Isselbacher KJ. Ranitidine: A new H2 receptor antagonist. N Engl J Med 1983; 309: 1368-73.
12. Bakır T, Minkar T, Arslan MK, Aygün E. Healing of gastric ulcer with ranitidine or high-dose of antacid. J Islamic Acad Sciences 1988; 1: 70-71.
13. Rubin W. Medical treatment of peptic ulcer disease. Med Clin North Am 1991; 75: 981-98.
14. Aygün E, Gedik Y, Arslan MK, Pişkin B. H2 reseptör antagonistleri (simetidin,ranitidin). Türkiye Klinikleri 1987; 7: 147-52.
15. Armstrong D, Arnold R, Classen M, et al. Prospective multicentre study of risk factors associated delayed healing of recurrent duodenal ulcers. Gut 1993; 34: 1319-26.
16. Knauer CM, Silverman S. Alimentary tract & liver. In: Schroeder SA, Krupp MA, Tierney LM, McPhee SJ (editors). Current Medical Diagnosis & Treatment. Lebanon: Apleton & Lange, 1991:396¬485.
17. Jensen DM, Cheng S, Kovacs TO, et al. A controlled study of ranitidine for the prevention of N Engl J Med 1994; 330: 382-6. recurrent hemorrhage from duodenal ulcer.

Thank you for copying data from http://www.arastirmax.com